Search Results - "Saigi, María"

Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer by Aparicio, Inmaculada, Iranzo, Patricia, Reyes, Roxana, Bote, Helena, Saigi, María, Bringas, Marianela, Bosch-Barrera, Joaquim, Corral, Jesús, Aparisi, Francisco, Ruffinelli, Jose C., Jiménez, Beatriz, Lage, Yolanda, López-Castro, Rafael, Majem, Margarita, Vázquez, Sergio, Artal, Ángel, Rodríguez-Pérez, Ángel, Lázaro-Quintela, Martín, Torres, José Miguel Sánchez, Reguart, Noemí, Cucurull, Marc, Gil-Bazo, Ignacio, Camps, Carlos, Nadal, Ernest, del Barrio, Anabel, Garrido, Pilar, Dómine, Manuel, Álvarez, Rosa, Muñoz, Andrés J., Calles, Antonio

“…INTRODUCTIONWe aimed to determine if advanced BRAF-mutant NSCLC has a higher thromboembolic events (TEE) rate than the expected.METHODSBetween 2008 and 2021,…”
Get full text

A Novel Epigenetic Signature for Early Diagnosis in Lung Cancer by Diaz-Lagares, Angel, Mendez-Gonzalez, Jesus, Hervas, David, Saigi, Maria, Pajares, Maria J, Garcia, Diana, Crujerias, Ana B, Pio, Ruben, Montuenga, Luis M, Zulueta, Javier, Nadal, Ernest, Rosell, Antoni, Esteller, Manel, Sandoval, Juan

“…Lung cancer remains as the leading cause of cancer-related death worldwide, mainly due to late diagnosis. Cytology is the gold-standard method for lung cancer…”
Get full text

Small-Cell Lung Cancer Long-Term Survivor Patients: How to Find a Needle in a Haystack? by Plaja, Andrea, Moran, Teresa, Carcereny, Enric, Saigi, Maria, Hernández, Ainhoa, Cucurull, Marc, Domènech, Marta

“…Small-cell lung cancer (SCLC) is an aggressive malignancy characterized by a rapid progression and a high resistance to treatments. Unlike other solid tumors,…”
Get full text

MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer by Yoshida, Ryohei, Saigi, Maria, Tani, Tetsuo, Springer, Benjamin F, Shibata, Hirofumi, Kitajima, Shunsuke, Mahadevan, Navin R, Campisi, Marco, Kim, William, Kobayashi, Yoshihisa, Thai, Tran C, Haratani, Koji, Yamamoto, Yurie, Sundararaman, Shriram K, Knelson, Erik H, Vajdi, Amir, Canadas, Israel, Uppaluri, Ravindra, Paweletz, Cloud P, Miret, Juan J, Lizotte, Patrick H, Gokhale, Prafulla C, Jänne, Pasi A, Barbie, David A

“…Immunotherapy has shown limited efficacy in patients with EGFR-mutated lung cancer. Efforts to enhance the immunogenicity of EGFR-mutated lung cancer have been…”
Get full text

SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade by Romero, Octavio A., Vilarrubi, Andrea, Alburquerque-Bejar, Juan J., Gomez, Antonio, Andrades, Alvaro, Trastulli, Deborah, Pros, Eva, Setien, Fernando, Verdura, Sara, Farré, Lourdes, Martín-Tejera, Juan F., Llabata, Paula, Oaknin, Ana, Saigi, Maria, Piulats, Josep M., Matias-Guiu, Xavier, Medina, Pedro P., Vidal, August, Villanueva, Alberto, Sanchez-Cespedes, Montse

“…Despite the genetic inactivation of SMARCA4 , a core component of the SWI/SNF-complex commonly found in cancer, there are no therapies that effectively target…”
Get full text

Immunogenicity of COVID-19 vaccines in lung cancer patients by Provencio, Mariano, Estival, Anna, Franco, Fernando, López-Vivanco, Guillermo, Saigí, María, Arasanz, Hugo, Diz, Pilar, Carcereny, Enric, García, Javier, Aguado, Carlos, Mosquera, Joaquín, Iruarrizaga, Eluska, Majem, Margarita, Bosch-Barrera, Joaquim, Mielgo-Rubio, Xavier, Guirado, María, Juan-Vidal, Óscar, Blasco, Ana, Lucía Gozálvez, Clara, Del Barrio, Anabel, De Portugal, Teresa, López-Martín, Ana, Serrano, Gloria, Campos, Begoña, Rubio, Judit, Catot, Silvia, Esteban, Beatriz, Martí-Ciriquian, Juan Luis, del Barco, Edel, Calvo, Virginia

“…•Lung cancer patients have higher risk of SARS-CoV-2 infection and severe complications.•Evaluating safety and immunogenicity of COVID-19 vaccine in 1973 lung…”
Get full text

Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data by Gutiérrez, Lourdes, Royuela, Ana, Carcereny, Enric, López-Castro, Rafael, Rodríguez-Abreu, Delvys, Massuti, Bartomeu, González-Larriba, José Luis, García-Campelo, Rosario, Bosch-Barrera, Joaquim, Guirado, María, Camps, Carlos, Dómine, Manuel, Bernabé, Reyes, Casal, Joaquín, Oramas, Juana, Ortega, Ana Laura, Sala, Mª Angeles, Padilla, Airam, Aguiar, David, Juan-Vidal, Oscar, Blanco, Remei, Del Barco, Edel, Martínez-Banaclocha, Natividad, Benítez, Gretel, de Vega, Blanca, Hernández, Ainhoa, Saigi, Maria, Franco, Fernando, Provencio, Mariano

“…There is a lack of useful diagnostic tools to identify EGFR mutated NSCLC patients with long-term survival. This study develops a prognostic model using real…”
Get full text

Identification Of Actionable Genetic Targets In Primary Cardiac Sarcomas by Salvador-Coloma, Carmen, Saigí, María, Díaz-Beveridge, Roberto, Penín, Rosa María, Pané-Foix, María, Mayordomo, Empar, Melián, Marcos, Schuler, Mona, García Del Muro, Xavier, Font de Mora, Jaime

“…Primary cardiac tumors are extremely rare; most are myxomas with a benign prognosis. However, primary sarcomas are highly aggressive and treatment options are…”
Get full text

Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies by Cucurull, Marc, Notario, Lucia, Sanchez-Cespedes, Montse, Hierro, Cinta, Estival, Anna, Carcereny, Enric, Saigí, Maria

“…Approximately 20% of lung adenocarcinomas harbor mutations, an oncogene that drives tumorigenesis and has the ability to alter the immune system and the tumor…”
Get full text

HLA-I levels correlate with survival outcomes in response to immune checkpoint inhibitors in non-small cell lung cancer by Saigí, Maria, Mate, Jose L., Carcereny, Enric, Martínez-Cardús, Anna, Esteve, Anna, Andreo, Felipe, Centeno, Carmen, Cucurull, Marc, Mesia, Ricard, Pros, Eva, Sanchez-Cespedes, Montse

“…•Additional predictive markers besides to PD-L1 are needed to select patients with NSCLC more accurately who would benefit from ICI strategies.•High levels of…”
Get full text

Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy by Bergamino, Milana, Rullan, Antonio J, Saigí, Maria, Peiró, Inmaculada, Montanya, Eduard, Palmero, Ramón, Ruffinelli, José Carlos, Navarro, Arturo, Arnaiz, María Dolores, Brao, Isabel, Aso, Samantha, Padrones, Susana, Cardenal, Felipe, Nadal, Ernest

“…Diabetes is related with increased cancer mortality across multiple cancer types. Its role in lung cancer mortality is still unclear. We aim to determine the…”
Get full text

Unraveling the Intricacies of CD73/Adenosine Signaling: The Pulmonary Immune and Stromal Microenvironment in Lung Cancer by Saigí, Maria, Mesía-Carbonell, Oscar, Barbie, David A, Guillamat-Prats, Raquel

“…CD73 and adenosine have gained prominence in lung cancer research. The gene encodes CD73, known as an ectonucleotidase, which plays a crucial role within tumor…”
Get full text

Biological and clinical perspectives of the actionable gene fusions and amplifications involving tyrosine kinase receptors in lung cancer by Saigí, Maria, Carcereny, Enric, Morán, Teresa, Cucurull, Marc, Domènech, Marta, Hernandez, Ainhoa, Martinez-Cardús, Anna, Pros, Eva, Sanchez-Cespedes, Montse

“…•Gene fusions and amplifications often activate receptor tyrosine kinases in lung cancer.•Next-generation sequencing is the gold standard for molecular…”
Get full text

Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C by Notario, Lucía, Cucurull, Marc, Cerdà, Gabriela, Sanz, Carolina, Carcereny, Enric, Muñoz-Mármol, Ana, Hernández, Ainhoa, Domènech, Marta, Morán, Teresa, Sánchez-Céspedes, Montse, Costa, Marta, Mate, Jose-Luis, Esteve, Anna, Saigí, Maria

“…Approximately 20% of lung adenocarcinomas harbor activating mutations at KRAS , an oncogene with the ability to alter the tumor immune microenvironment. In…”
Get full text

Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma by Aliagas, Elisabet, Alay, Ania, Martínez-Iniesta, Maria, Hernández-Madrigal, Miguel, Cordero, David, Gausachs, Mireia, Pros, Eva, Saigí, Maria, Busacca, Sara, Sharkley, Annabel J., Dawson, Alan, Palmero, Ramón, Ruffinelli, José C., Padrones, Susana, Aso, Samantha, Escobar, Ignacio, Ramos, Ricard, Llatjós, Roger, Vidal, August, Dorca, Eduard, Varela, Mar, Sánchez-Céspedes, Montse, Fennell, Dean, Muñoz-Pinedo, Cristina, Villanueva, Alberto, Solé, Xavi, Nadal, Ernest

“…Background There is no effective therapy for patients with malignant pleural mesothelioma (MPM) who progressed to platinum-based chemotherapy and…”
Get full text

Clinical relevance of histologic subtypes in locally advanced esophageal carcinoma treated with pre-operative chemoradiotherapy: Experience of a monographic oncologic centre by Saigí, Maria, Oliva, Marc, Aliste, Luisa, Calvo, Mariona, Hormigo, Gloria, Serra, Òlbia, Boladeras, Anna, Farran, Leandre, Robles, Javier, Creus, Gloria, Paúles, Ma José, Gornals, Joan B, de Lama, Eugenia, Borràs, Josep Ma, Sala, Núria, Galán, Maica

“…Locally advanced esophageal carcinoma (LAEC) represents less than 30% of all diagnosed esophageal carcinoma worldwide. The standard of care for resectable…”
Get full text

Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front by Saigi, Maria, Alburquerque-Bejar, Juan J., Sanchez-Cespedes, Montse

“…The incorporation into clinical practice of immune-checkpoint inhibitors (ICIs), such as those targeting the cytotoxic T lymphocyte-associated antigen 4…”
Get full text

Abstract 998: Searching for genetic alterations that drive the capability of evading tumor immunosurveillance in lung cancer by Alburquerque-Bejar, Juan Jose, Saigi, Maria, Pros, Eva, Romero, Octavio, Sanchez-Cespedes, Montse

“…Abstract Background The capability of tumors to avoid immune surveillance has emerged as therapeutically approachable, especially through the blockade of…”
Get full text

MET-oncogenic and JAK2-inactivating alterations are independent factors that affect regulation of PD-L1 expression in lung cancer by Saigi, Maria, Alburquerque-Bejar, Juan J, McLEER-Florin, Anne, Pereira, Carolina, Pros, Eva, Romero, Octavio A, Baixeras, Nuria, Esteve-Codina, Anna, Nadal, Ernest, Brambilla, Elisabeth, Sanchez-Cespedes, Montse

“…The blockade of immune checkpoints such as PD-L1 and PD-1 is being exploited therapeutically in several types of malignancies. Here, we aimed to understand the…”
Get full text

Is oligoprogression a potentially curable disease in epidermal growth factor receptor mutant lung adenocarcinoma? by Chekhun, Sviatoslav, Lopez-Paradís, Assumpció, Urbizu, Aintzane, Morán, Teresa, Mañes, Anabel, Cucurull, Marc, Martínez-Barenys, Carlos, Teruel, Iris, Moragas, Gloria, Carcereny, Enric, Muñoz Mármol, Ana Maria, Saigí, Maria

“…Third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have shown impressive results in mutant lung cancer (LC) patients in…”
Get full text